Table Of Contents:

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size by Service Type

  2.3.2 Market Size by Application

  2.3.3 Market Size by Indication

  2.3.4 Market Size by End-User

 2.4 Market Share & Bps Analysis by Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

     3.4 Industry Supply Chain Analysis

3.4.1 Raw Material & Technology Providers

3.4.2 mRNA CDMO Manufacturers & Service Providers

3.4.3 Distribution, Logistics & Regulatory Partners

3.4.4 Biopharmaceutical Companies & Research Organizations

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 mRNA Drug Development & Clinical Pipeline Trends (2025)

4.1.1 Global mRNA Therapeutics Pipeline by Development Phase

4.1.2 Growth in mRNA Clinical Trials by Therapeutic Area

4.1.3 Personalized mRNA Therapeutics Development Trends

4.1.4 mRNA Outsourcing Activity Across Development Stages

4.2 mRNA Manufacturing Capacity & CDMO Trends (2025)

4.2.1 Global mRNA Manufacturing Capacity Expansion Trends

4.2.2 CDMO Outsourcing Penetration in mRNA Therapeutics

4.2.3 GMP mRNA Production Demand Analysis

4.2.4 Lipid Nanoparticle (LNP) Manufacturing Capacity Trends

4.3 Biopharmaceutical R&D Investment Trends (2025)

4.3.1 mRNA Therapeutics R&D Funding by Region

4.3.2 Biotech and Pharmaceutical Investments in mRNA Platforms

4.3.3 Strategic Partnerships and Licensing Activity Trends

4.3.4 Venture Capital Investment in mRNA Therapeutics Companies

4.4 Regulatory & Commercialization Trends (2025)

4.4.1 Regulatory Framework Developments for mRNA Therapeutics

4.4.2 IND and CTA Filing Trends for mRNA Candidates

4.4.3 Approval Activity for mRNA-Based Products

4.4.4 Quality, GMP Compliance & CMC Requirements Trends

4.5 Innovation, Technology & Market Development Trends (2025)

4.5.1 Self-Amplifying mRNA (saRNA) Development Trends

4.5.2 Next-Generation Lipid Nanoparticle (LNP) Technology Trends

4.5.3 AI-Driven mRNA Design and Optimization Trends

4.5.4 Automation and Digitalization in mRNA Manufacturing Trends

5. MRNA Therapeutics Contract Development & Manufacturing Market Segmental Analysis & Forecast, By Service Type, 2022 – 2035, Value (USD Billion)

     5.1 Introduction

   5.2 Contract Manufacturing

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022 – 2035

5.3 Drug Development Services

5.4 Analytical & Testing Services

5.5 Regulatory & Compliance Services

5.6 Others

6. MRNA Therapeutics Contract Development & Manufacturing Market Segmental Analysis & Forecast, By Application, 2022 – 2035, Value (USD Billion)

    6.1 Introduction

    6.2 Viral Vaccines

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022 – 2035

6.3 Protein Replacement Therapies

6.4 Cancer Immunotherapy

6.5 Rare Genetic Disease Therapies

6.6 Others

7. MRNA Therapeutics Contract Development & Manufacturing Market Segmental Analysis & Forecast, by Indication, 2022 – 2035, Value (USD Billion)

    7.1 Introduction

    7.2 Infectious Diseases

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022 – 2035

7.3 Metabolic & Genetic Diseases

7.4 Oncology

7.5 Cardiovascular Diseases

7.6 Others

8. MRNA Therapeutics Contract Development & Manufacturing Market Segmental Analysis & Forecast, By End-User, 2022 – 2035, Value (USD Billion)

    8.1 Introduction 

  8.2 Biotechnology Companies

   8.2.1 Key Trends 

   8.2.2 Market Size & Forecast, 2022 – 2035 

8.3 Pharmaceutical Companies

8.4 Academic & Research Institutions

8.5 Government & Non-Profit Organizations

9. MRNA Therapeutics Contract Development & Manufacturing Market Segmental Analysis & Forecast by Region, 2022 – 2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Service Type, 2022 – 2035

 9.2.3 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Application, 2022 – 2035

 9.2.4 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, by Indication, 2022 – 2035

 9.2.5 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By End-User, 2022 – 2035

 9.2.6 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Country, 2022 – 2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Service Type, 2022 – 2035

 9.3.3 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Application, 2022 – 2035

 9.3.4 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, by Indication, 2022 – 2035

 9.3.5 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By End-User, 2022 – 2035

 9.3.6 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Country, 2022 – 2035

  9.3.6.1 Germany

  9.3.6.2 United Kingdom

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Service Type, 2022 – 2035

 9.4.3 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Application, 2022 – 2035

 9.4.4 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, by Indication, 2022 – 2035

 9.4.5 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By End-User, 2022 – 2035

 9.4.6 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Country, 2022 – 2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Service Type, 2022 – 2035

 9.5.3 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Application, 2022 – 2035

 9.5.4 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, by Indication, 2022 – 2035

 9.5.5 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By End-User, 2022 – 2035

 9.5.6 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Country, 2022 – 2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Service Type, 2022 – 2035

 9.6.3 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Application, 2022 – 2035

 9.6.4 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, by Indication, 2022 – 2035

 9.6.5 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By End-User, 2022 – 2035

 9.6.6 MRNA Therapeutics Contract Development & Manufacturing Market Size & Forecast, By Country, 2022 – 2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 Egypt

  9.6.6.5 South Africa

  9.6.6.6 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022 – 2025

  10.2.3 Number of Strategies Adopted by Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Network Type Benchmarking

  10.4.1 Product/Service Specifications & Features by Key Players

  10.4.2 Product/Service Heatmap by Key Players

  10.4.3 Network Type Heatmap by Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Lonza Group AG

  10.6.1.1 Company Overview & Snapshot

  10.6.1.2 Product/Service Portfolio

  10.6.1.3 Key Company Financials

  10.6.1.4 SWOT Analysis

10.6.2 Catalent Inc. (Novo Holdings)

10.6.3 Thermo Fisher Scientific Inc. (Patheon)

10.6.4 Aldevron LLC (Danaher Corporation)

10.6.5 TriLink BioTechnologies

10.6.6 Wacker Biotech GmbH

10.6.7 AGC Biologics

10.6.8 Recipharm AB

10.6.9 Samsung Biologics Co. Ltd.

10.6.10 WuXi Biologics Co. Ltd.

10.6.11 BIOMAY AG

10.6.12 Kaneka Eurogentec S.A.

10.6.13 eTheRNA immunotherapies nv

10.6.14 Biocina d.o.o.

10.6.15 Arcturus Therapeutics Holdings

10.6.16 CureVac SE

10.6.17 Precision BioSciences Inc.

10.6.18 ProQR Therapeutics

10.6.19 Orna Therapeutics

10.6.20 Moderna Inc.

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List of Tables

 14.2 List of Figures